<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155205</url>
  </required_header>
  <id_info>
    <org_study_id>LX1606.1-105-NRM</org_study_id>
    <secondary_id>LX1606.105</secondary_id>
    <nct_id>NCT02155205</nct_id>
  </id_info>
  <brief_title>A Thorough QT Study of Telotristat Etiprate</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Positive Controlled, 3-period, 6-sequence, Crossover Study to Define the Electrocardiogram Effects of a Single Dose of Telotristat Etiprate (LX1606) 1500 mg Compared With Placebo and Open Label Moxifloxacin in Healthy Subjects: A Thorough QT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that telotristat etiprate does not differ from
      placebo in the mean change from Baseline QT interval corrected for heart rate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline QT interval corrected for heart rate</measure>
    <time_frame>Days 1-3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>52 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of telotristat etiprate</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>QT Interval</condition>
  <arm_group>
    <arm_group_label>Telotristat etiprate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of telotristat etiprate followed by a 7-day washout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of moxifloxacin followed by a 7-day washout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo with a 7-day washout to follow.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telotristat etiprate</intervention_name>
    <description>1500 mg telotristat etiprate (six 250 mg tablets)</description>
    <arm_group_label>Telotristat etiprate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400 mg moxifloxacin (one 400 mg tablet)</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males or females ≥18 to ≤55 years of age (inclusive) at the time of
             Screening

          -  Body mass index ≥18 to ≤32 kg/m2 at Screening

          -  Vital signs (after at least 5 minutes resting in a supine position) at Screening which
             are within the following ranges: Systolic blood pressure 90 to 140 mm Hg, Diastolic
             blood pressure 50 to 90 mm Hg, heart rate 45 to 100 beats per minute (bpm)

          -  Clinical laboratory evaluations (including clinical chemistry panel [fasted at least
             10 hours], complete blood count, and urinalysis [UA]) within the reference range for
             the test laboratory, unless deemed not clinically significant by the Investigator

          -  Able to tolerate prolonged periods of quiet, motionless, supervised rest

          -  Willing to adhere to the prohibitions and restrictions specified in this protocol

          -  Able to comprehend and willing to sign an Informed Consent Form

        Exclusion Criteria:

          -  Presence of clinically significant physical, laboratory, or ECG findings at Screening
             that, in the opinion of the Investigator or Sponsor, may interfere with any aspect of
             study conduct or interpretation of results

          -  &gt;30 premature ventricular beats per hour on the Holter ECG monitoring at Day -1 of
             Period 1 (monitored at the clinic via telemetry)

          -  History of additional risk factors for torsade de pointes or the diagnosis or
             suggestion of a family history of short QT syndrome or long QT syndrome

          -  History of renal disease or significantly abnormal kidney function tests

          -  History of hepatic disease or significantly abnormal liver function tests

          -  History of any clinically significant psychiatric, renal, hepatic, pancreatic,
             cardiovascular, neurological, or gastrointestinal abnormality

          -  Concurrent conditions that could interfere with safety and tolerability measurements

          -  Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus
             antibody) or positive human immunodeficiency virus antibody screens

          -  Use of tobacco, use of medications, or history of any disease or condition that might
             interfere with the conduct of the study in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Wason, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <last_update_submitted>September 5, 2014</last_update_submitted>
  <last_update_submitted_qc>September 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

